Amplified luminescent proximity homogeneous assay

Amplified Luminescence Proximity Homogeneous Assay (AlphaS-creen ) technology have been reported [50,51]. With an HTS methodology in hand and orthogonal assays previously developed [47-49], nonpeptide antagonists of methyl lysine binding should appear from diversity screening approaches in the near future. 

AlphaScreen (amplified luminescent proximity homogeneous assay) PerkinElmer Life Sciences Donor beads produce singlet oxygen that induces fluorescence in proximal acceptor beads bead-bead proximity results from engagement of binding partners immobilized on the two bead types... 

In order to avoid the described problems, antibody-based assays have been developed. As mentioned above, usually a primary antibody recognizes the modification, which in turn is then quantitated. One of these approaches is based on the technology of AlphaScreen (Amplified luminescent Proximity Homogeneous Assay) [51, 52], also known as luminescent oxygen channeling immunoassay (LOCI) [53], a method that can be used to study protein-protein interactions in general. In this case the enzymatic transfer of acetyl groups to a histone peptide is determined. 

Amplified Luminescent Proximity Homogeneous Assay (AlphaScreen )... 

The Amplified Luminescent Proximity Homogeneous Assay (AlphaScreen ) developed by BioSignal, is a bead-based, non-radioactive assay technology. It uses the principle of luminescent oxygen channeling, which was first described in 1994 by Ullman [173], who two years later demonstrated a broad spectrum of applications for such immunoassays [174]. This principle senses the proximity of two beads, a donor and an acceptor bead, which is mediated by the interaction of molecules on the surfaces of the two beads. 

AlphaScreen Amplified luminescence proximity homogeneous assay... 

---